Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
2 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
3 Chemical carcinogenesis - receptor activation 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
4 Chemokine signaling pathway 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
5 Cholinergic synapse 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
6 Coronavirus disease - COVID-19 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
7 EGFR tyrosine kinase inhibitor resistance 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
8 Epstein-Barr virus infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
9 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
10 Hepatitis B 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
11 Hepatitis C 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
12 Herpes simplex virus 1 infection 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
13 Human cytomegalovirus infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
14 Human papillomavirus infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
15 Human T-cell leukemia virus 1 infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
16 Influenza A 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
17 JAK-STAT signaling pathway 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
18 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
19 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
20 Lipid and atherosclerosis 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
21 Measles 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
22 Necroptosis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
23 NOD-like receptor signaling pathway 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
24 Osteoclast differentiation 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
25 Pancreatic cancer 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
26 Pathways in cancer 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
27 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
28 PI3K-Akt signaling pathway 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
29 Prolactin signaling pathway 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
30 Signaling pathways regulating pluripotency of stem cells 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
31 Th1 and Th2 cell differentiation 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
32 Th17 cell differentiation 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
33 Toxoplasmosis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
34 Tuberculosis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
35 Viral carcinogenesis 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬

先頭へ